Market Closed -
Nasdaq
01:30:00 22/06/2024 am IST
|
5-day change
|
1st Jan Change
|
0.5125
USD
|
-3.30%
|
|
-21.12%
|
-82.51%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
564.3
|
104.6
|
25.86
|
119.3
|
21.09
|
-
|
-
|
Enterprise Value (EV)
1 |
411.7
|
20.55
|
-48.31
|
119.3
|
-19.11
|
-47.61
|
-73.41
|
P/E ratio
|
-4.93
x
|
-2.46
x
|
-0.56
x
|
-2.36
x
|
-0.41
x
|
-0.55
x
|
-0.59
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
11.8
x
|
3.39
x
|
8.84
x
|
6.39
x
|
EV / Revenue
|
-
|
-
|
-
|
11.8
x
|
-3.07
x
|
-20
x
|
-22.2
x
|
EV / EBITDA
|
-1,40,11,550
x
|
-4,89,413
x
|
10,23,258
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-1,49,18,977
x
|
-5,71,431
x
|
11,58,691
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
0.94
x
|
-0.17
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
23,214
|
23,463
|
23,560
|
40,711
|
41,155
|
-
|
-
|
Reference price
2 |
24.31
|
4.460
|
1.097
|
2.930
|
0.5125
|
0.5125
|
0.5125
|
Announcement Date
|
22/03/21
|
14/03/22
|
16/03/23
|
13/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
10.09
|
6.222
|
2.386
|
3.3
|
EBITDA
|
-29.38
|
-42
|
-47.21
|
-
|
-
|
-
|
-
|
EBIT
1 |
-29.42
|
-42.07
|
-47.28
|
-51.99
|
-50.45
|
-56.09
|
-65.91
|
Operating Margin
|
-
|
-
|
-
|
-515.34%
|
-810.82%
|
-2,351.08%
|
-1,997.25%
|
Earnings before Tax (EBT)
1 |
-29.54
|
-42.29
|
-46.18
|
-47.92
|
-49.33
|
-51.93
|
-67.1
|
Net income
1 |
-29.54
|
-42.29
|
-46.18
|
-47.92
|
-51.01
|
-52.79
|
-65.15
|
Net margin
|
-
|
-
|
-
|
-474.96%
|
-819.86%
|
-2,212.63%
|
-1,974.33%
|
EPS
2 |
-4.930
|
-1.810
|
-1.960
|
-1.240
|
-1.252
|
-0.9383
|
-0.8675
|
Free Cash Flow
|
-27.59
|
-35.97
|
-41.69
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/03/21
|
14/03/22
|
16/03/23
|
13/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
1.964
|
2.165
|
3.073
|
2.887
|
2.002
|
1.282
|
1.354
|
1.053
|
0.65
|
0.65
|
EBITDA
|
-9.115
|
-
|
-11.87
|
-11.54
|
-12.09
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.135
|
-11.73
|
-11.88
|
-11.56
|
-12.11
|
-13.2
|
-13.97
|
-13.66
|
-11.16
|
-12.63
|
-12.9
|
-12.58
|
-12.13
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-672.05%
|
-645.36%
|
-444.45%
|
-386.7%
|
-631.02%
|
-1,006.4%
|
-929.59%
|
-1,151.36%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-9.184
|
-11.76
|
-11.87
|
-11.4
|
-11.14
|
-12.79
|
-12.82
|
-12.35
|
-9.95
|
-11.62
|
-13.28
|
-12.34
|
-12.09
|
-
|
-
|
Net income
1 |
-9.184
|
-11.76
|
-11.87
|
-11.4
|
-11.14
|
-12.79
|
-12.82
|
-12.35
|
-9.95
|
-11.62
|
-13.62
|
-13.2
|
-12.54
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-651.27%
|
-592.33%
|
-402.02%
|
-344.65%
|
-580.67%
|
-1,062.09%
|
-975.57%
|
-1,190.7%
|
-
|
-
|
EPS
2 |
-0.3900
|
-0.5000
|
-0.5100
|
-0.4800
|
-0.4700
|
-0.4000
|
-0.3200
|
-0.3000
|
-0.2300
|
-0.2800
|
-0.3275
|
-0.3200
|
-0.3000
|
-0.2500
|
-0.2350
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
14/03/22
|
11/05/22
|
10/08/22
|
10/11/22
|
16/03/23
|
15/05/23
|
14/08/23
|
13/11/23
|
13/03/24
|
13/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
153
|
84.1
|
74.2
|
-
|
40.2
|
68.7
|
94.5
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-27.6
|
-36
|
-41.7
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
4.740
|
-6.350
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-4.590
|
-1.540
|
-1.770
|
-
|
-
|
-
|
-
|
Capex
|
0.07
|
0.09
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/03/21
|
14/03/22
|
16/03/23
|
13/03/24
|
-
|
-
|
-
|
Last Close Price
0.5125
USD Average target price
2.5
USD Spread / Average Target +387.80% Consensus |
1st Jan change
|
Capi.
|
---|
| -82.51% | 21.09M | | +34.14% | 51.12B | | -6.54% | 39.4B | | +34.92% | 38.48B | | +12.62% | 26.36B | | -12.11% | 26.22B | | -13.43% | 20.96B | | +43.73% | 14.02B | | +31.81% | 12.49B | | -4.54% | 11.61B |
Other Biotechnology & Medical Research
|